Details

Autor(en) / Beteiligte

• Phuong, Nguyen Thi Ngoc
• Manh, Dao Huy
• Dumre, Shyam Prakash
• Mizukami, Shusaku
• Weiss, Lan Nguyen
• Van Thuong, Nguyen
• Ha, Tran Thi Ngoc
• Phuc, Le Hong
• Van An, Tran
• Tieu, Thuan Minh
• Kamel, Mohamed Gomaa
• Morra, Mostafa Ebraheem
• Huong, Vu Thi Que
• Huy, Nguyen Tien
• Hirayama, Kenji

Titel

Plasma cell-free DNA: a potential biomarker for early prediction of severe dengue

Ist Teil von

• Annals of clinical microbiology and antimicrobials, 2019-03, Vol.18 (1), p.10-10, Article 10

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2019

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Considerable progress has been made in dengue management, however the lack of appropriate predictors of severity has led to huge number of unwanted admissions mostly decided on the grounds of warning signs. Apoptosis related mediators, among others, are known to correlate with severe dengue (SD) although no predictive validity is established. The objective of this study was to investigate the association of plasma cell-free DNA (cfDNA) with SD, and evaluate its prognostic value in SD prediction at acute phase. This was a hospital-based prospective cohort study conducted in Vietnam. All the recruited patients were required to be admitted to the hospital and were strictly monitored for various laboratory and clinical parameters (including progression to SD) until discharged. Plasma samples collected during acute phase (6-48 h before defervescence) were used to estimate the level of cfDNA. Of the 61 dengue patients, SD patients (n = 8) developed shock syndrome in 4.8 days (95% CI 3.7-5.4) after the fever onset. Plasma cfDNA levels before the defervescence of SD patients were significantly higher than the non-SD group (p = 0.0493). From the receiver operating characteristic (ROC) curve analysis, a cut-off of > 36.9 ng/mL was able to predict SD with a good sensitivity (87.5%), specificity (54.7%), and area under the curve (AUC) (0.72, 95% CI 0.55-0.88; p = 0.0493). Taken together, these findings suggest that cfDNA could serve as a potential prognostic biomarker of SD. Studies with cfDNA kinetics and its combination with other biomarkers and clinical parameters would further improve the diagnostic ability for SD.